A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
Primary Purpose
Glaucoma, Ocular Hypertension (OH)
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Latanoprost-PPDS
Sponsored by
About this trial
This is an interventional treatment trial for Glaucoma
Eligibility Criteria
Inclusion Criteria:
- Male or female at least 18 years old
- Diagnosis of bilateral open angle glaucoma or ocular hypertension
- Unmedicated IOP must be ≥22mm Hg
Exclusion Criteria:
- Any significant vision loss in the last year
- No contact lens use for the length of the study
- Abnormal eye lids, eye infection or diseases to the eye
- Recent eye surgery
- Uncontrolled medical conditions
Sites / Locations
- Vold Vision
- Glaucoma Consultants of Colorado, PC
- Danbury Eye Physicians & Surgeons
- Ophthalmology Consultants Inc.
- Ophthalmology Associates
- Comprehensive Eye Care, Ltd
- Las Vegas Physicians Research Group
- Abrams Eye Institute
- Philadelphia Eye Associates
- University Eye Surgeons
- Total Eye Care, P.A.
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Treatment A
Treatment B
Treatment C
Arm Description
Outcomes
Primary Outcome Measures
IOP change from baseline
Secondary Outcome Measures
Full Information
NCT ID
NCT01481077
First Posted
November 25, 2011
Last Updated
September 19, 2013
Sponsor
Mati Therapeutics Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01481077
Brief Title
A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
Official Title
PPL GLAU 13: A Randomized Phase 2 Study of the Effect of Plug Placement on Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)
Study Type
Interventional
2. Study Status
Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
September 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mati Therapeutics Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine the effect of plug placement on the efficacy, safety and duration of effect of the L-PPDS (latanoprost punctal plug delivery system).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma, Ocular Hypertension (OH)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
77 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment A
Arm Type
Experimental
Arm Title
Treatment B
Arm Type
Experimental
Arm Title
Treatment C
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Latanoprost-PPDS
Intervention Description
Sustained release for 12 weeks
Primary Outcome Measure Information:
Title
IOP change from baseline
Time Frame
12 weeks to baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female at least 18 years old
Diagnosis of bilateral open angle glaucoma or ocular hypertension
Unmedicated IOP must be ≥22mm Hg
Exclusion Criteria:
Any significant vision loss in the last year
No contact lens use for the length of the study
Abnormal eye lids, eye infection or diseases to the eye
Recent eye surgery
Uncontrolled medical conditions
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Suzanne Cadden
Organizational Affiliation
QLT Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Vold Vision
City
Springdale
State/Province
Arkansas
ZIP/Postal Code
72762
Country
United States
Facility Name
Glaucoma Consultants of Colorado, PC
City
Denver
State/Province
Colorado
ZIP/Postal Code
80134
Country
United States
Facility Name
Danbury Eye Physicians & Surgeons
City
Danbury
State/Province
Connecticut
ZIP/Postal Code
06810
Country
United States
Facility Name
Ophthalmology Consultants Inc.
City
Des Peres
State/Province
Missouri
ZIP/Postal Code
63131
Country
United States
Facility Name
Ophthalmology Associates
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63131
Country
United States
Facility Name
Comprehensive Eye Care, Ltd
City
Washington
State/Province
Missouri
ZIP/Postal Code
63090
Country
United States
Facility Name
Las Vegas Physicians Research Group
City
Henderson
State/Province
Nevada
ZIP/Postal Code
89052
Country
United States
Facility Name
Abrams Eye Institute
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89148
Country
United States
Facility Name
Philadelphia Eye Associates
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19148
Country
United States
Facility Name
University Eye Surgeons
City
Maryville
State/Province
Tennessee
ZIP/Postal Code
37803
Country
United States
Facility Name
Total Eye Care, P.A.
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
We'll reach out to this number within 24 hrs